BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30

• Business

  Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results

  Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported recent business and pipeline progress and third quarter 2022 financial results.

  November 10, 2022

   · 

  12 min read
• Business

  Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

  Cabaletta Bio, Inc. reported financial results for the third quarter ended September 30, 2022, and provided a business update.

  November 10, 2022

   · 

  11 min read
• Business

  Talaris Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update

  Talaris Therapeutics, Inc. reported financial results for the three- and nine-month periods ended September 30, 2022 and provided an update on its business.

  November 10, 2022

   · 

  8 min read
• Business

  Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update

  Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the three and nine months ended September 30, 2022, and provided a business update.

  November 10, 2022

   · 

  12 min read
• Business

  Jounce Therapeutics Reports Third Quarter 2022 Financial Results

  Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

  November 10, 2022

   · 

  13 min read
• Business

  Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

  Aravive, Inc., a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, reported financial results for the third quarter ended September 30, 2022 and provided corporate updates.

  November 10, 2022

   · 

  14 min read
• Biotech Beach

  Element Introduces New Element LoopSeq™ Long-Read Sequencing Kits Designed for the AVITI™ System

  Element Biosciences, Inc. announced the availability of its Element LoopSeq long-read sequencing technology kits for AVITI, giving the Element AVITI System the power of both short- and long-read sequencing on the same instrument.

  November 10, 2022

   · 

  3 min read
• Business

  Seagen Names David R. Epstein as Chief Executive Officer and Director

  Seagen Inc. (Nasdaq: SGEN) today announced that its Board of Directors has appointed David R. Epstein as Chief Executive Officer (CEO) and a member of the Board of Directors.

  November 10, 2022

   · 

  5 min read
• Business

  Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights

  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended September 30, 2022.

  November 10, 2022

   · 

  14 min read
• Business

  Apyx Medical Corporation Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook

  Apyx Medical Corporation today reported financial results for its third quarter ended September 30, 2022, and updated financial expectations for the full year ending December 31, 2022.

  November 10, 2022

   · 

  18 min read